Foster City, CA, United States of America

Venkat R Thalladi

USPTO Granted Patents = 42 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 118(Granted Patents)

Location History:

Santa Clara, CA (US) (2013 - 2014)
Foster City, CA (US) (2013 - 2023)

Company Filing History:

37 out of 262

Theravance Biopharma R&d Ip, LLC

Years Active: 2013-2025

Loading Chart...

42 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12351561 - Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2025-07-08),

2. 11795180 - Formulation of a pan-JAK inhibitor (2023-10-24),

3. 11780852 - Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2023-10-10),

4. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease (2023-08-08),

5. 11718591 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof (2023-08-08),

6. 11642332 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid (2023-05-09),

7. 11452723 - Combination dosage form of a mu opioid receptor antagonist and an opioid agent (2022-09-27),

8. 11230536 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof (2022-01-25),

9. 11160810 - Fused imidazo-piperidine JAK inhibitor compound (2021-11-02),

10. 11160800 - Methods of treatment using a JAK inhibitor compound (2021-11-02),

11. 11033533 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid (2021-06-15),

12. 10968205 - Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors (2021-04-06),

13. 10947254 - Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (2021-03-16),

14. 10946009 - Combination dosage form of a mu opioid receptor antagonist and an opioid agent (2021-03-16),

15. 10913740 - JAK kinase inhibitor compounds for treatment of respiratory disease (2021-02-09),

Title: Venkat R Thalladi: Innovator in Pharmaceutical Sciences

Introduction: Venkat R Thalladi is a prominent inventor located in Foster City, CA, known for his significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 41 patents, he has made notable advancements in drug formulation and treatment methods.

Latest Patents: Among his latest patents, Thalladi has focused on the formulation of a pan-JAK inhibitor. This invention relates to pharmaceutical compositions that include a specific compound, which serves critical therapeutic uses. Additionally, he has developed methods for treating Crohn's disease using the same compound, highlighting his commitment to addressing serious health conditions through innovative solutions.

Career Highlights: Thalladi's career is marked by stints at reputable organizations, such as Theravance Biopharma R&D IP, LLC and Theravance, Inc. His work within these companies has played a vital role in advancing research in pharmacology and drug development, positioning him as a leader in his field.

Collaborations: Throughout his career, Thalladi has collaborated with notable professionals, including Miroslav Rapta and Melissa Fleury. These partnerships have allowed him to further enhance his research and development initiatives, contributing to impactful innovations in the pharmaceutical industry.

Conclusion: Venkat R Thalladi exemplifies the spirit of innovation in pharmaceuticals with his numerous patents and successful collaborations. His work continues to pave the way for groundbreaking treatments, especially in conditions like Crohn's disease, reinforcing the importance of ongoing research and development in healthcare.

This text is generated by artificial intelligence and may not be accurate.